Corporate Responsibility Strategy

Integrate corporate responsibility into Pfizer's core business processes
2009 Goal 2009 Progress
Increase Board-level oversight of the corporate responsibility function Began providing biannual corporate responsibility updates to the Corporate Governance Committee of Pfizer's Board of Directors on specific progress on corporate responsibility goals.
Engage colleagues in all Pfizer geographies and business units in corporate responsibility Established a Global Corporate Responsibility Colleague Network that links individuals working in roles associated with corporate responsibility in more than 30 countries. Membership now includes more than 100 individuals. Meetings are held quarterly.
Establish approach for regular feedback on Pfizer's corporate responsibility reporting and performance Met with select stakeholders individually to obtain initial feedback on Pfizer's 2009 report and conducted a survey of select investors. Based on feedback and survey findings, determined that Pfizer should begin to integrate some elements of corporate responsibility reporting in Annual Review beginning in 2010 and fully integrate the Corporate Responsibility Report with the Annual Review beginning in 2011.

Facilitate responsible transitions during the economic recession
2009 Goal 2009 Performance
Provide laid-off Pfizer employees with resources to find new employment, careers or other opportunities Provided laid-off Pfizer employees (including legacy Wyeth employees) with comprehensive separation packages, which included resources to find new employment, careers, or other opportunities and financial education/planning to facilitate the transition to other opportunities.
Enhance internal clarity about changes at Pfizer associated with the proposed acquisition of Wyeth

Employees from Pfizer and Wyeth were a core focus of a communications plan that set the tone for the combined company and helped unite employees around a common goal and mission. The program focused on generating an understanding of the strategic benefits of the acquisition, excitement for Pfizer's future, and explaining the interim processes and integration procedures taking place. On the first day of combined operations, the Chairman and CEO issued an "all-colleague" e-mail and hosted two global town hall broadcasts that reached close to 40,000 employees. Staffed and stand-alone information displays were positioned at over 300 sites in 150 countries and communications materials were made available in almost 20 different languages.

An employee survey indicated that Pfizer's communications efforts were well received. The Financial Times noted Pfizer's internal communications and how it demonstrated the company's dedication to a successful integration. Anecdotal reactions from vendors, suppliers and business partners made it clear that Pfizer continued to meet its business goals and commitments in a time of change.

Access to Medicines

Improve public health around the world
2009 Goal 2009 Performance
Explore strategies that improve health care through new, nontraditional business models that are commercially viable, scalable and sustainable

Continued to learn more about customer needs and priorities; launched pilot programs to increase access to key medicines and innovative products for low-income patients in emerging markets.

Developed strong partnerships for delivery of, and increased access to, our products.

Expanded partnerships in the development of new business models that improve access to medicines and health care.

Broaden access to medicines and strengthen health care delivery for underserved people around the world Continued ongoing strategic social investments, which include the deployment of people, products, and funding in partnership with governments and nongovernmental, multilateral and private organizations. Three examples represent a sample of our work to strengthen health care around the world: 232 Pfizer Global Health Fellows have volunteered in the past six years to serve with nongovernmental organizations improving health care in 39 countries; $1.1 billion in medicine has been donated since 2000 through the Diflucan Partnership to treat fungal infections associated with HIV/AIDS; and $47 million in grants is being provided to organizations engaging in innovative cancer and tobacco control initiatives through a collaboration between Pfizer and the Pfizer Foundation.

Patient Safety

Develop and implement a program to protect the integrity of Pfizer medicines
2009 Goal 2009 Performance
Identify and disrupt major manufacturers of counterfeit Pfizer products

During 2009, authorities from 42 countries reported seizing almost 11 million counterfeit dosages of Pfizer medicines. Many of these seizures were the result of evidence obtained by Pfizer Global Security and then referred to authorities for their action.

Those seizures were the result of 285 raids conducted by the authorities, a 37.7 percent increase over 2008, and resulted in 626 arrests, a 30.9 percent increase over 2008.

Develop effective partnerships with enforcement and regulatory authorities around the world Work in progress to enlist support of key officials in anti-counterfeiting efforts through Memoranda of Understanding.
Raise awareness of the risks that counterfeit medicines pose to patients Provided fact-based support for Pfizer's policy initiatives with respect to anti-counterfeiting activities.

Research & Development

Improve patient health worldwide by developing promising new medicines to treat the world's
most serious diseases
2009 Goal 2009 Performance
Continue to advance our development pipeline from Phase I through registration, especially in the high priority disease areas Advanced 15 new molecular entities and new indications to Phase III during the 2008-2009 period, which resulted in a total of 27 legacy Pfizer programs in Phase III at the end of 2009. In addition, we added seven Phase III programs through our acquisition of Wyeth, increasing our total number of Phase III programs at year-end 2009 to 34 programs.
Use the new Business Unit (BU) model to ensure that these efforts remain responsive to the changing needs of patients worldwide Organized 17 small, nimble and entrepreneurial Research Units and Biotechnology Units led by Chief Scientific Officers to drive research programs forward. These units work closely with the Biopharmaceutical Business Units in advancing a steady flow of differentiated investigational medicines through clinical development. Multiple promising molecules were transferred to the business units in 2009, including potential treatments for lung cancer and Alzheimer's disease.
Ensure that our Research and Development efforts remain aligned with our goal to expand research in neglected diseases Continued our public-private partnerships in the development of new treatments for malaria, development of maraviroc as a microbiocide for HIV, and the joint venture with GlaxoSmithKline on new HIV/AIDS treatments. Advanced PNU-100480, a potential new TB treatment, into clinical trials. Developed new partnerships with the Drugs for Neglected Diseases Initiative and several academic research institutions to expand screening efforts for African sleeping sickness, visceral leishmaniasis and Chagas disease.
Continue to invest in new technologies that will allow better utilization of our medicines by physicians and patients Continued investment in development of biomarkers and diagnostic tools that allow better patient and physician utilization of our therapies.
Expand our commitment to maintaining the highest ethical standards and transparency in our conduct of human clinical trials worldwide

Received accreditation for our human subject protection program from the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for our Phase I clinical trial units in the U.S., Singapore and Belgium. This is the first and only accreditation granted by AAHRPP to any pharmaceutical company. We maintained leadership in registering all of our interventional trials, with 1,302 trials registered as of February 2010 on We continue to publicly post summary results of these trials following approval of the drug (or within one year of trial completion or termination of development, as applicable), with 1,018 results summaries posted by Pfizer on In 2010, Pfizer will be the first company to publicly disclose our clinical trial payments made to U.S. investigators and their institutions.

Pfizer's Chief Medical Officer and General Counsel hosted a summit with other companies, nongovernmental organizations, academics and others to discuss ways to improve the conduct of multiregional clinical trials, for which a report is now being finalized. Pfizer also began creating, with the University of Hong Kong, a manual for ethics committees and their members about multiregional clinical trials, trial design and the important role of ethics committees in reviewing these trials.

We partnered with local institutions to provide scientific and research ethics training to over 1,000 investigators, scientists, research ethics committee members, and others in China, Korea, Mexico, India and Africa.

Our key research policies, along with commitments to comply with the principles of the Declaration of Helsinki and other standards, are posted on at s/policies_positions_casestudies.jsp

Environmental Health & Safety

Reduce our impact on the physical environment
2009 Goal 2009 Performance
Continue to reduce our GHG emissions Continued to take measures to reduce our GHG emissions. Pfizer was recognized globally for achievement of the 2000-2007 greenhouse gas intensity goal, its pledge to reduce CO2 emissions on an absolute basis 2009-2012, and its comprehensive disclosure of, and focused approach to, addressing some of the risks and opportunities associated with a changing climate. The Carbon Disclosure Project (CDP) named Pfizer to its Climate Disclosure Leadership Index, which highlights the company's climate change disclosure practices. This is the third year that Pfizer has been recognized by CDP.
Develop a more strategic approach to environmental sustainability as part of Corporate Responsibility platform Launched a new environmental sustainability strategy that includes more strategic and integrated approaches to our environmental initiatives, embedding environmental sustainability into the business.

Public Policy

Support U.S. health care system reform
2009 Goal 2009 Performance
Take a leadership role in U.S. health care reform policy debates Actively supported health care reform that expands comprehensive health care coverage, improves quality and provides value for patients without eliminating current choices or reducing health care innovation; established stakeholder advisory board to get input on health care reform and facilitate broader dialogue.
Assist in bridging the current gap in prescription coverage for Americans who have recently lost coverage due to unemployment Launched a new Pfizer Helpful Answers® patient assistance program called Pfizer MAINTAIN™. The program is designed to help unemployed Americans without prescription coverage, who are in financial need, continue to get their Pfizer medicine free-of-charge for up to 12 months or until they become insured (whichever comes first).